Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Izzy who wrote (2785)	11/14/1997 5:04:00 PM
From: JOHN W.	Read Replies (1) of 6136

Subject: Pharmacology Date: Fri, Nov 14, 1997 09:33 EST From: LMoss Message-id: <19971114143300.JAA16195@ladder01.news.aol.com> Contrary to a statement posted recently, Fortovase is indeed saquinavir, but in a soft gel formulation. The purpose of the new formulation is to slow down its release in the body, where it is quickly metabolized by the liver. In its original formulation, only about 4% of ingested saquinavir was biologically effective, and rapid metabolization reduced serum concentrations below those thought to be necessary during part of the day. Accordingly, saquinavir was not one of the protease inhibitors recommended by the NIH panel for HAART treatment of HIV. The soft gel formulation will increase bioavailability to about 14%, and moderate the sharp peak-and-valley concentration produced by the original formulation. Another approach is to slow down the rate of metabolization of saquinavir. One of the drugs that happens to do this is Viracept. Taken with saquinavir, it increases the bioavailability of the latter to about 20%. Taken with saq's soft-gel formulation (Fortovase) it should do even better. That is one reason this combination may prove to be the PI treatment of choice. LMoss

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next